Highlight
• Therapeutic-dose anticoagulation in noncritically ill hospitalized COVID-19 patients reduces progression to organ support or death compared to prophylactic doses.
• Early coordinated platform trials enabled timely evidence generation, but delays in data sharing and synthesis slowed clinical guideline updates.
• Individual participant data meta-analysis (IPDMA) provided robust evidence, highlighting the value of real-time cross-trial collaboration.
• Strengthening infrastructure for coordinated research, funding, and rapid data synthesis is critical for future public health emergencies.
Study Background
The COVID-19 pandemic has posed major challenges to healthcare systems worldwide, including the need to rapidly generate and incorporate clinical evidence to improve outcomes. One of the major complications in COVID-19 is coagulopathy, predisposing hospitalized patients to thrombosis, which can progress to critical illness and death. Early observational studies suggested potential benefit of anticoagulation, but optimal dosing strategies—prophylactic versus therapeutic anticoagulation—remained uncertain, especially in noncritically ill patients hospitalized with COVID-19.
Given the urgency and novelty of COVID-19, the typical processes of evidence generation, synthesis, and translation into clinical guidelines were compressed and stressed. This created an opportunity to evaluate how randomized controlled trials (RCTs) evaluating anticoagulation strategies were conducted, combined, and translated into practice guidance, with the aim to glean lessons for future health emergencies.
Study Design
A systematic review and individual participant data meta-analysis (IPDMA) were performed focusing on RCTs comparing therapeutic-dose versus nontherapeutic (primarily prophylactic) dose anticoagulation in noncritically ill hospitalized COVID-19 patients. The analysis incorporated seven RCTs with a combined total of 6,362 patients, with individual participant-level data obtained through coordinated data transfer by April 2024.
Endpoints included the composite outcome of organ support (such as mechanical ventilation or vasopressor use) or death, and safety outcomes including major bleeding events. The pooled treatment effects were estimated using mixed-effects logistic regression models, reflecting both within- and between-trial variability.
Key Findings
The evidence synthesis supported a significant benefit for therapeutic-dose anticoagulation in reducing progression to organ support or death among noncritically ill hospitalized patients with COVID-19. Specifically, the pooled incidence of organ support or death was 12.9% in patients receiving therapeutic anticoagulation versus 16.2% in controls, yielding an adjusted odds ratio (OR) of 0.81 (95% confidence interval [CI], 0.67–0.97).
Major bleeding remained rare, reported in 0.8% of the therapeutic anticoagulation group versus 0.5% in the control group, indicating an acceptable safety profile in this patient population.
Chronologically, the earliest evidence was generated from coordinated platform RCTs published as preprints in May 2021, approximately 13 months after the first patient enrollment. Subsequent RCTs published through July 2023 corroborated these findings. An exploratory counterfactual sequential IPDMA demonstrated that statistically significant treatment effects could have been identified as early as May 2021 by pooling data from six RCTs with 3,944 participants.
Reflecting these data, clinical guidelines initially recommended prophylactic-dose anticoagulation in 2020. However, by 2022, guidelines evolved to support therapeutic-dose anticoagulation strategies in noncritically ill COVID-19 patients, though certainty of evidence varied between guideline bodies.
Expert Commentary
The accelerated research in therapeutic anticoagulation during COVID-19 exemplifies both the power and challenges of rapid evidence generation in a public health emergency. Coordinated, adaptive platform trials facilitated faster answers than traditional trial designs might have allowed, highlighting a key strategy for improving research responsiveness.
However, delays in data sharing, difficulties in rapid synthesis, and heterogeneity in guideline interpretation slowed optimal integration into clinical practice. The IPDMA approach using individual participant data across RCTs provided a more granular, reliable estimate of treatment effects and safety, reinforcing the value of cross-trial collaboration and data transparency.
Notwithstanding, limitations include variability in trial designs, populations, and anticoagulation protocols, which may affect generalizability. Additionally, therapeutic dosing requires clinical judgment balancing thrombotic risk against bleeding, particularly in patients with comorbidities.
Conclusion
The COVID-19 anticoagulation experience underscores critical lessons for future pandemics and health crises: strengthening coordinated research infrastructure, fostering near-real-time data sharing, prioritizing funding for adaptive trials, and developing mechanisms for rapid, robust evidence synthesis and guideline updating. Therapeutic-dose anticoagulation in noncritically ill hospitalized COVID-19 patients has a demonstrated benefit for reducing organ support or death with a low incidence of major bleeding, providing a clear example of informed clinical practice shaped by evolving evidence under uncertainty.
Adopting these lessons could improve the timeliness and reliability of evidence systems, ultimately enhancing patient outcomes in future public health emergencies.
Funding and Clinical Trials Registration
The included studies and the meta-analyses were supported by collaborative consortia involving academic institutions and governmental funding agencies globally. Details on individual trial registrations can be accessed through respective clinical trial registries.
References
1. Tritschler T, Fuster V, Lawler PR, et al. Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients. J Am Coll Cardiol. 2026;88(4):437-450. PMID: 42523015.
2. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N Engl J Med. 2021;385(9):790-802.
3. NIH COVID-19 Treatment Guidelines Panel. Antithrombotic Therapy in Patients with COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/.
